Skip to content
2000
Volume 25, Issue 11
  • ISSN: 1566-5240
  • E-ISSN: 1875-5666

Abstract

Background

Ovarian cancer is one of the deadliest gynecologic cancers, with chemotherapy resistance as the greatest clinical challenge. Autophagy occurrence is associated with cisplatin (DDP)-resistant ovarian cancer cells. Herein, the role and mechanism of alpha-synuclein (SNCA), the autophagy-related gene, in DDP resistance of ovarian cancer cells are explored.

Methods

Differentially expressed genes in DDP resistance of ovarian cancer cells were analyzed by GEO2R tools. DDP-resistant ovarian cancer cells (A2780/DDP) were transfected and treated with 2.5 µg/mL DDP for 72 h, followed by the determination of cell viability, proliferation, apoptosis, and expressions of SNCA, lysine demethylase 4A (KDM4A), histone H3 lysine 9 trimethylation (H3K9me3), and mitophagy-related proteins. The H3K9me3 demethylation of SNCA by KDM4A was confirmed by chromatin immunoprecipitation.

Results

SNCA and KDM4A were highly expressed in DDP-resistant ovarian cancer cells and their parental cells. KDM4A knockdown diminished expressions of KDM4A and SNCA and elevated H3K9me3 expression and H3K9me3 enrichment on SNCA promoter in A2780/DDP cells. SNCA or KDM4A knockdown inhibited cell viability, proliferation, and levels of LC3-II/LC3-I and Parkin while inducing cell apoptosis and upregulating Cyt-C expression of A2780/DDP cells with/without DDP treatment; however, SNCA overexpression not only did conversely but also reversed the effects of KDM4A knockdown on DDP-treated A2780/DDP cells and vice versa.

Conclusion

Silencing of KDM4A-mediated transcription inactivation of SNCA reduces mitophagy, thus inhibiting the resistance of ovarian cancer cells to cisplatin. KDM4A may be a promising drug target for DDP-resistant ovarian cancer cells.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmm/10.2174/0115665240281083241112053145
2025-01-08
2025-12-23

  • From This Site

    /content/journals/cmm/10.2174/0115665240281083241112053145
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. SungH. FerlayJ. SiegelR.L. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J. Clin.202171320924910.3322/caac.21660 33538338
     [Google Scholar]
  2. LagaT. VergoteI. Van NieuwenhuysenE. Immunotherapy in rare ovarian cancer.Curr. Opin. Oncol.202133544745610.1097/CCO.0000000000000759 34230441
     [Google Scholar]
  3. LuH.Y. TaiY.J. ChenY.L. ChiangY.C. HsuH.C. ChengW.F. Ovarian cancer risk score predicts chemo-response and outcome in epithelial ovarian carcinoma patients.J. Gynecol. Oncol.2021322e1810.3802/jgo.2021.32.e18 33327048
     [Google Scholar]
  4. BhardwajB.K. ThankachanS. VenkateshT. SureshP.S. Liquid biopsy in ovarian cancer.Clin. Chim. Acta2020510283410.1016/j.cca.2020.06.047 32622965
     [Google Scholar]
  5. SongM. CuiM. LiuK. Therapeutic strategies to overcome cisplatin resistance in ovarian cancer.Eur. J. Med. Chem.202223211420510.1016/j.ejmech.2022.114205 35217497
     [Google Scholar]
  6. BerkelC. CacanE. Estrogen- and estrogen receptor (ER)-mediated cisplatin chemoresistance in cancer.Life Sci.202128612002910.1016/j.lfs.2021.120029 34634322
     [Google Scholar]
  7. LeT.N. HarveyR.E. KimC.K. BrownJ. ColemanR.L. SmithJ.A. A retrospective evaluation of activity of gemcitabine/platinum regimens in the treatment of recurrent ovarian cancer.Gynecol. Oncol. Res. Pract.2017411610.1186/s40661‑017‑0053‑x 29158911
     [Google Scholar]
  8. MaedaO. KajiyamaH. ShibataK. Pegylated liposomal doxorubicin/oxaliplatin chemotherapy can overcome cisplatin resistance in spectrin αII-overexpressing ovarian carcinoma.Anticancer Res.40520202497250710.21873/anticanres.14220 32366394
     [Google Scholar]
  9. NachtigalMW SchweizerF ArthurG Abstract A56: Novel Lsugar linked glycosylated antitumor ether lipids for killing platinum-resistant human epithelial ovarian cancer cells.Clin Cancer Res26(Suppl 13)A56.202010.1158/1557‑3265.OVCA19‑A56
     [Google Scholar]
  10. ZhouY. WangC. DingJ. ChenY. SunY. ChengZ. miR-133a targets YES1 to reduce cisplatin resistance in ovarian cancer by regulating cell autophagy.Cancer Cell Int.20222211510.1186/s12935‑021‑02412‑x 35012539
     [Google Scholar]
  11. QiG. MaH. LiY. PengJ. ChenJ. KongB. TTK inhibition increases cisplatin sensitivity in high-grade serous ovarian carcinoma through the mTOR/autophagy pathway.Cell Death Dis.20211212113510.1038/s41419‑021‑04429‑6 34876569
     [Google Scholar]
  12. BlažekovićA. JerčićK.G. BorovečkiF. SNCA 3′ UTR genetic variants in patients with Parkinson’s disease.Biomolecules11121799202110.3390/biom11121799 34944443
     [Google Scholar]
  13. UgaldeC.L. LawsonV.A. FinkelsteinD.I. HillA.F. The role of lipids in α-synuclein misfolding and neurotoxicity.J. Biol. Chem.2019294239016902810.1074/jbc.REV119.007500 31064841
     [Google Scholar]
  14. YanY XuZ HuX SNCA is a functionally low-expressed gene in lung adenocarcinoma20189:16
     [Google Scholar]
  15. ZhouL. ZhengH. TianY. SNCA inhibits epithelial–mesenchymal transition and correlates to favorable prog-nosis of breast cancer.Carcinogenesis202243111071108210.1093/carcin/bgac078 36179220
     [Google Scholar]
  16. WuZ. XiaC. ZhangC. YangD. MaK. Prognostic significance of SNCA and its methylation in bladder cancer.BMC Cancer202222133010.1186/s12885‑022‑09411‑9 35346107
     [Google Scholar]
  17. MartinezJ.H. AlaimoA. GorojodR.M. Drp-1 dependent mitochondrial fragmentation and protective autophagy in dopaminergic SH-SY5Y cells overexpressing alpha-synuclein.Mol. Cell. Neurosci.20188810711710.1016/j.mcn.2018.01.004 29414102
     [Google Scholar]
  18. SongJ.X. LuJ.H. LiuL.F. HMGB1 is involved in autophagy inhibition caused by SNCA/α-synuclein overexpression.Autophagy201410114415410.4161/auto.26751 24178442
     [Google Scholar]
  19. SutopoN.C. KimJ.H. ChoJ.Y. Role of histone methylation in skin cancers: Histone methylation–modifying enzymes as a new class of targets for skin cancer treatment.Biochim. Biophys. Acta Rev. Cancer20231878318886510.1016/j.bbcan.2023.188865 36841366
     [Google Scholar]
  20. LeeK-H KimB-C JeongS-H Histone demethylase KDM7A regulates androgen receptor activity, and its chemical inhibitor TC-E 5002 overcomes cisplatin-resistance in bladder cancer cells2020Int. J. Mol. Sci.2116565810.3390/ijms21165658
     [Google Scholar]
  21. ChangS.L.Y. LeeC.W. YangC.Y. IOX-1 suppresses metastasis of osteosarcoma by upregulating histone H3 lysine trimethylation.Biochem. Pharmacol.202321011547210.1016/j.bcp.2023.115472 36863615
     [Google Scholar]
  22. CharidemouE. KoufarisC. LoucaM. KirmizisA. Rubio-TomásT. Histone methylation in pre-cancerous liver diseases and hepatocellular carcinoma: Recent overview.Clin. Transl. Oncol.20232561594160510.1007/s12094‑023‑03078‑9 36650321
     [Google Scholar]
  23. KimT.D. ShinS. JanknechtR. ETS transcription factor ERG cooperates with histone demethylase KDM4A.Oncol. Rep.20163563679368810.3892/or.2016.4747 27109047
     [Google Scholar]
  24. YangG. LiC. TaoF. The emerging roles of lysine-specific demethylase 4A in cancer: Implications in tumori-genesis and therapeutic opportunities.Genes Dis.202411264566310.1016/j.gendis.2022.12.020 37692513
     [Google Scholar]
  25. ChenM. JiangY. SunY. KDM4A-mediated histone demethy-lation of SLC7A11 inhibits cell ferroptosis in osteosarcoma.Biochem. Biophys. Res. Commun.2021550778310.1016/j.bbrc.2021.02.137 33689883
     [Google Scholar]
  26. LivakK.J. SchmittgenT.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method.Methods200125440240810.1006/meth.2001.1262 11846609
     [Google Scholar]
  27. WangJ. LiuL. MiR-149-3p promotes the cisplatin resistance and EMT in ovarian cancer through downregulating TIMP2 and CDKN1A.J. Ovarian Res.202114116510.1186/s13048‑021‑00919‑5 34798882
     [Google Scholar]
  28. RenY. HeX. YanX. Unravelling the polytoxicology of chlorfenapyr on non-target HepG2 cells: The involvement of mitochondria-mediated programmed cell death and DNA damage.Molecules20222717572210.3390/molecules27175722 36080487
     [Google Scholar]
  29. PedersenC.C. LangeJ. FørlandM.G.G. MacleodA.D. AlvesG. Maple-GrødemJ. A systematic review of associations between common SNCA variants and clinical heterogeneity in Parkinson’s disease.NPJ Parkinsons Dis.2021715410.1038/s41531‑021‑00196‑5 34210990
     [Google Scholar]
  30. WangQ. TianQ. SongX. LiuY. LiW. SNCA gene polymorphism may contribute to an increased risk of alzheimer’s disease.J. Clin. Lab. Anal.30620161092109910.1002/jcla.21986
     [Google Scholar]
  31. BrueningW. GiassonB.I. Klein-SzantoA.J.P. LeeV.M.Y. TrojanowskiJ.Q. GodwinA.K. Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneo-plastic lesions of the ovary.Cancer20008892154216310.1002/(SICI)1097‑0142(20000501)88:9<2154:AID‑CNCR23>3.0.CO;2‑9 10813729
     [Google Scholar]
  32. EvanG.I. VousdenK.H. Proliferation, cell cycle and apoptosis in cancer.Nature2001411683534234810.1038/35077213
     [Google Scholar]
  33. ZhangL. RenH. WuY. XueL BaiY. WeiD WuQ XueL. BaiY. WeiD. WuQ. PRG4 represses the genesis and metastasis of osteosarcoma by inhibiting PDL1 expression.Tissue Cell20248810240910.1016/j.tice.2024.102409
     [Google Scholar]
  34. IchimiyaT. YamakawaT. HiranoT. Autophagy and autophagy-related diseases: A review.Int. J. Mol. Sci.20202123897410.3390/ijms21238974 33255983
     [Google Scholar]
  35. MavroeidiP. ArvanitakiF. VetsiM. Autophagy mediates the clearance of oligodendroglial SNCA/alpha-synuclein and TPPP/p25A in multiple system atrophy models.Autophagy20221892104213310.1080/15548627.2021.2016256 35000546
     [Google Scholar]
  36. ShenD-F QiH-P ZhangW-N SangW-X Resveratrol promotes autophagy to improve neuronal injury in Parkinson's disease by regulating SNHG1/miR-128-3p/SNCA axis.Brain Sci2023138112410.3390/brainsci13081124
     [Google Scholar]
  37. FangL. LvJ. XuanZ. Circular CPM promotes chemoresistance of gastric cancer via activating PRKAA2-mediated autophagy.Clin. Transl. Med.2022121e70810.1002/ctm2.708
     [Google Scholar]
  38. ZhangH LuB. The roles of ceRNAs-mediated autophagy in cancer chemoresistance and metastasis.Cancers (Basel)12102926.2020;10.3390/cancers12102926
     [Google Scholar]
  39. ChenT. ZengC. LiZ. Investigation of chemoresistance to first-line chemotherapy and its possible association with autophagy in high-risk neuroblastoma.Front. Oncol.202212101910610.3389/fonc.2022.1019106
     [Google Scholar]
  40. YanC. LiT.S. Dual role of mitophagy in cancer drug resistance.Anticancer Res.2018382617621 29374684
     [Google Scholar]
  41. MaM. LinX.H. LiuH.H. ZhangR. ChenR.X. Suppression of DRP1 mediated mitophagy increases the apoptosis of hepatocellular carcinoma cells in the setting of chemotherapy.Oncol. Rep.20204331010101810.3892/or.2020.7476 32020220
     [Google Scholar]
  42. VianelloC. CocettaV. CatanzaroD. Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy.Cell Death Dis.202213439810.1038/s41419‑022‑04741‑9 35459212
     [Google Scholar]
  43. HuX. WangJ. ChaiJ. Chaetomugilin J enhances apoptosis in human ovarian cancer A2780 cells induced by cisplatin through inhibiting Pink1/Parkin mediated mitophagy.OncoTargets Ther.2020139967997610.2147/OTT.S273435 33116582
     [Google Scholar]
  44. FritzenA.M. FrøsigC. JeppesenJ. Role of AMPK in regulation of LC3 lipidation as a marker of autophagy in skeletal muscle.Cell. Signal.201628666367410.1016/j.cellsig.2016.03.005 26976209
     [Google Scholar]
  45. Guerra-CalderasL. González-BarriosR. HerreraL.A. Cantú de LeónD. Soto-ReyesE. The role of the histone demethylase KDM4A in cancer.Cancer Genet.2015208521522410.1016/j.cancergen.2014.11.001 25633974
     [Google Scholar]
  46. ZhaoJ. LiB. RenY. Histone demethylase KDM4A plays an oncogenic role in nasopharyngeal carcinoma by promoting cell migration and invasion.Exp. Mol. Med.20215381207121710.1038/s12276‑021‑00657‑0 34385569
     [Google Scholar]
/content/journals/cmm/10.2174/0115665240281083241112053145
Loading
KDM4A Silencing Reverses Cisplatin Resistance in Ovarian Cancer Cells by Reducing Mitophagy via SNCA Transcriptional Inactivation
Current Molecular Medicine 25, 1372 (2025); https://doi.org/10.2174/0115665240281083241112053145
/content/journals/cmm/10.2174/0115665240281083241112053145
/content/journals/cmm/10.2174/0115665240281083241112053145
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): alpha-synuclein; cisplatin resistance; histone methylation; Lysine demethylase 4A; mitophagy; ovarian cancer

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test